Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
Bio-Techne (NASDAQ: TECH) has partnered with Lunaphore to create an automated spatial multiomics workflow aimed at enhancing research in disease analysis and therapeutic development. This collaboration integrates Bio-Techne's RNAscope™ technology with Lunaphore's seqIF™ system for simultaneous detection of protein and RNA biomarkers. The innovative solution promises flexibility in panel designs and is expected to streamline workflows for researchers focused on various diseases, including cancer and neurodegenerative disorders. With RNAscope™'s extensive catalog of over 45,000 probes and proven sensitivity, the partnership aims to significantly accelerate the discovery of novel diagnostics and therapeutics.
Bio-Techne Corporation (NASDAQ: TECH) announced its participation in the American Association for Cancer Research (AACR) annual meeting from April 14-19, 2023, in Orlando, Florida. The company will showcase its extensive portfolio of products aimed at advancing cancer research and facilitating cell and gene therapy development. Featured products include reagents, immunoassays, proteomic instruments, and spatial biology solutions. Several scientists from Bio-Techne will present posters on topics such as biomarkers, structural biology, and spatial biology. Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and employs about 3,000 people globally.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on May 3, 2023, at 8:00 a.m. CDT to discuss its third quarter 2023 financial results. Investors can dial in at 1-877-300-8521 for U.S. calls or 1-412-317-6026 for international calls, using Conference ID 10177426. A rebroadcast will be available for those unable to join live, from 11:00 a.m. CDT on May 3 to 11:00 p.m. CDT on June 3, 2023. Bio-Techne is a leader in developing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales for fiscal 2022 and employing around 3,000 employees globally.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
